Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells

Anticancer Research

Volumn 27, Issue 3 B, 2007, Pages 1387-1392

  Sun, Ying ^a   Eichelbaum, Ehrentraud J ^a   Hai, Wang ^a   Vesely, David L ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Adenocarcinoma; Kaliuretic peptide; MEK 1 2 kinase; Natriuretic peptides; Prostate neoplasm; Vessel dilator

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIC GMP; CYCLIC GMP ANTIBODY; KALIURETIC PEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PEPTIDE ANTIBODY; UNCLASSIFIED DRUG; VESSEL DILATOR;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOCARCINOMA; ANTIBODIES; ANTINEOPLASTIC AGENTS; ATRIAL NATRIURETIC FACTOR; CELL LINE, TUMOR; CYCLIC GMP; ENZYME ACTIVATION; HUMANS; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS;

EID: 34249288341     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Scholl FA, Dumesic PA and Khavari PA: Effects of active MEK 1 expression in vivo. Cancer Lett 230: 1-5, 2005.
2. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangeliste C, Martelli AM and Franklin RA: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta, in press, Available online October 7, 2006.
3. Crews CM, Alessandrini A and Erikson RL: The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 258: 478-480, 1992.
4. Wu J, Harrison JK, Dent P, Lynch KR, Weber MJ and Sturgill TW: Identification and characterization of a new mammalian mitogen-activated protein kinase kinase MKK-2. Mol Cell Biol 13: 4539-4548, 1993.
5. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells. Anticancer Res 26: 3217-3222, 2006.
6. Waldman SA, Rapoport RM and Murad F: Atrial natriuretic factor selectively activates membranous guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 259: 14332-14334, 1984.
7. Vesely DL: Signal transduction: activation of guanylate cyclase-cyclic guanosine-3′-5′ monophosphate system by hormones and free radicals. Am J Med Sci 314: 311-323, 1997.
8. Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF: Isolation of a human prostate carcinoma cell line (DU-145). Int J Cancer 21: 274-281, 1978.
9. Vesely BA, Alli AA, Song S, Gower WR Jr, Sanchez-Ramos J and Vesely DL: Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest 35: 700-710, 2005.
10. Vesely BA, McAfee Q, Gower WR Jr and Vesely DL: Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 33: 998-1005, 2003.
11. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Solivan SM, Gower WR Jr and Vesely DL: Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest 35: 60-69, 2005.
12. Gower WR Jr, Vesely BA, Alli AA and Vesely DL: Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via guanosine 3′,5′-cyclic monophosphate. Int J Gastrointestinal Cancer 36: 77-88, 2005.
13. Vesely BA, Fitz SR, Gower WR Jr and Vesely DL: Vessel dilator: Most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of squamous lung cancer cells. Cancer Lett 232: 226-231, 2006.
14. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Alli A, Solivan SM, Gower WR Jr and Vesely DL: Five cardiac hormones decrease the number of human small-cell cancer cells. Eur J Clin Invest 35: 388-398, 2005.
15. Vesely DL, Clark LC, Garces AH, McAfee QW, Soto J and Gower WR Jr: Novel therapeutic approach for cancer using four cardiovascular hormones. Eur J Clin Invest 34: 674-682, 2004.